Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

s IL-23p19 antibody picankibart to treat moderate to severe plaque psoriasis, and Lepu Biopharma’s antibody-drug conjugate MRG-003, to treat recurrent or metastatic nasopharyngeal cancer. Jiangsu ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Avidity’s advancements in siRNA modifications and antibody engineering have shown significant ... Avidity Biosciences (RNA) Company Description: Avidity Biosciences Inc is a bio-technology company.

Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment. The research, which was funded by the blood ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Avidity Biosciences (RNA – Research Report). The ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

It’s the first part of what the company describes will grow to become a multimodal suite for biopharma researchers that will span antibody-drug conjugates ... therapies and siRNA drugs as ...

Together, these solutions will offer researchers a multimodal approach to therapeutic discovery supporting CAR-T cell discovery, siRNA, antibody-drug conjugates (ADCs), CRISPR therapeutics ...